IPF Preclinical CRO Guide: Bleomycin, PCLS & Ashcroft (2026)

Lead: Choosing an IPF preclinical CRO is not about finding a vendor that runs bleomycin — every fibrosis CRO does. The real decisions are: Who scores Ashcroft reproducibly? Who delivers bleomycin by which route? Who can run it in aged mice? Who has human PCLS from actual IPF patients? Generic fibrosis CRO comparisons (see our Fibrosis CRO Landscape 2026) miss these IPF-specific capability splits. This guide fills that gap.

Key Takeaways

• The 4 technical axes that separate IPF-capable CROs: Ashcroft automation, PCLS access, bleomycin delivery, aged-mouse capability
• Capability-map for Lovelace Biomedical, FibroFind, ReproCELL, BioModels, and Charles River
• Selection flowchart by project stage (Ph0 mechanism → Ph1 efficacy → IND-enabling)
• 4 public-information checkpoints to verify "IPF specialty" claims

📢 Editorial Disclosure This article is independently edited. We receive no financial compensation, advertising fees, or affiliate commissions from any of the 5 CROs mentioned. Ordering and evaluation are based on company websites, PubMed publications, press releases, and ClinicalTrials.gov. See full disclosure at the end.

---

1. Why generic fibrosis CROs fall short for IPF

The hardest part of IPF preclinical work isn't picking a model — it's running the model with enough discipline to survive Phase 3 translation. Pirfenidone and nintedanib were reproducible in bleomycin mice. But Pamrevlumab (ZEPHYRUS-1) missed its primary endpoint in Phase 3, and Bexotegrast (BEACON-IPF) was discontinued in June 2025 at the Phase 2b stage of its Phase 2b/3 adaptive design — due to an imbalance in IPF-worsening adverse events, despite an efficacy signal. Both had encouraging preclinical or earlier-stage rationale, but late-stage outcomes diverged. These failures illustrate how hard it is to predict clinical success from bleomycin efficacy alone — they argue for orthogonal validation spanning mechanism, safety, and human-tissue data, rather than implying that "having a model guarantees success" or that "poor model execution caused the failures." The practical gap is less "does this CRO have a fibrosis model?" and more "does this CRO run the model in a way that supports orthogonal de-risking of human translation?"

Four capabilities separate IPF-capable CROs from generic fibrosis vendors:

Dimension	Generic fibrosis CRO	Additional IPF-specific requirement
Induction	BDL / CCl4 / DEN for liver	Bleomycin delivery options (IT / OP aspiration / micro-sprayer / osmotic pump)
Readout	Collagen quantification (HYP, Sirius Red)	Ashcroft score reproducibility (inter-rater ICC, AI-automated scoring)
Human translation	Liver slices, organoids	Human PCLS (precision-cut lung slices) from actual IPF donor tissue
Age	8-12 week-old mice standard	Aged mouse (18-24 months) for senescence-aware efficacy

---

2. Five-CRO capability matrix for IPF

CRO	HQ	Bleomycin routes	Ashcroft automation	Human lung PCLS	Aged mice	Alt. inducers
Lovelace Biomedical	USA (Albuquerque)	bleomycin rodent model (IT central; OP / aerosol micro-sprayer to confirm)	△ (manual, AI not publicly disclosed)	△ (mouse PCLS available; human PCLS case-by-case, confirm)	◇ (confirm directly)	Radiation / silica (deep inhalation-exposure experience)
FibroFind	UK (Newcastle)	✕ (publicly, ex vivo PCTS-centric)	N/A	◎ (human liver/kidney/IPF-lung PCTS, patented tissue bioreactor)	N/A	Ex vivo TGF-β / bleomycin stimulation
ReproCELL	Japan / UK (Tokyo / Glasgow)	✕ (publicly, ex vivo-centric)	N/A	○ (PCLS from healthy + COPD/asthma donors; IPF documented separately as a 3D tissue model — confirm PCLS/IPF-donor availability and fibrosis cocktail directly)	N/A	Ex vivo antifibrotic screening
BioModels	USA (Waltham, MA)	IT bleomycin (OP to confirm)	△ (manual + image analysis)	✕	◇ (confirm directly)	lung collagen / lung mechanics / DL-based IHC
Charles River	Global (USA, EU)	mouse/rat bleomycin (IT/OP/aerosol route details to confirm)	○ (image analysis pipeline, modified Ashcroft)	◇ (via partner — confirm)	◇ (confirm directly)	Silica / FITC / radiation

Legend: ◎ explicit on company site · ○ multiple case studies · △ limited / case-by-case · ◇ not confirmable from the public page alone = ask in RFP · ✕ not offered (per public info)

Note: This matrix is built mainly from what each company's public pages document. Items marked ◇ (confirm directly) cannot be asserted from public information — read them not as strengths but as items to confirm in the RFP (delivery route, PCLS tissue source, aged-mouse track record, GLP setup).

Business-model groupings

1. In vivo specialist × respiratory depth: Lovelace Biomedical (also inhalation toxicology, radiation injury)
2. Ex vivo specialist × human PCLS: FibroFind, ReproCELL
3. In vivo generalist × IPF option: BioModels, Charles River

---

3. Company profiles: strengths, use cases, caveats

3-1. Lovelace Biomedical (Albuquerque, USA) — Respiratory veteran with multi-inducer depth

Strengths: Descended from the Lovelace Respiratory Research Institute (LRRI), which has run respiratory research since the 1950s. Beyond standard bleomycin, Lovelace offers radiation-induced, silica-induced, and asbestos-induced pulmonary fibrosis models — far beyond most peers.

Bleomycin delivery: Public pages support a bleomycin rodent model plus alternative inducers (radiation, silica) and broad respiratory / inhalation-exposure experience. Specific routes such as IT, oropharyngeal (OP) aspiration, and aerosol (micro-sprayer) are not all confirmable from public information alone, so confirm route availability in the RFP. Micro-sprayer, in general, distributes drug evenly across airway epithelium and is used when spatial lesion heterogeneity would otherwise confound readout (see tech_pulmonary_fibrosis_model_en for delivery-route troubleshooting).

When to pick Lovelace:

• Ph0/Ph1 biotech wanting to test mechanism robustness across multiple inducers (bleo + radiation + silica)
• Inhaled-delivery formulations (nebulizer / dry-powder) that need integrated pharmacology + fibrosis readout under one roof

Caveats:

• No public disclosure of AI-based Ashcroft automation as of April 2026. Request inter-rater ICC data before committing
• Smaller scale than Charles River — confirm parallel-study capacity for larger IND programs

📎 Reference: Lovelace Biomedical — Pulmonary Fibrosis

---

3-2. FibroFind (Newcastle, UK) — Human PCLS pure-play

Strengths: UK-based CRO dedicated to ex vivo human tissue platforms for fibrosis. Their patented tissue bioreactor maintains patient-derived PCLS under physiological conditions for days to a week. Covers liver, kidney, and lung.

IPF use cases:

• Mechanism confirmation for a Phase 2 candidate that showed efficacy in mice — does it reproduce on human fibroblasts?
• Human-response ranking across multiple compounds when in vivo rankings are too close to call
• Benchmark against pirfenidone/nintedanib in a single-run design

Caveats:

• Publicly, the offering is ex vivo human-tissue PCTS-centric (in vivo animal work appears out of scope)
• Human PCLS is donor-limited: a lead time of several weeks to assemble a required cohort is realistic
• GLP capability is not confirmable from public information — confirm in the RFP (appears discovery-stage centric)

📎 Reference: FibroFind — Human tissue precision-cut slices

---

3-3. ReproCELL (Tokyo / Glasgow) — Routine human PCLS + fibrosis-cocktail IPF model

Strengths: Dual HQ in Japan and the UK. Offers human-tissue-based preclinical evaluation routinely. Public materials confirm healthy, COPD, and asthma donor-derived PCLS as the mainstay supply. IPF-like pathology is typically modeled via fibrosis cocktail (TGF-β + PDGF + TNF + LPA) stimulation on donor PCLS rather than sourcing actual IPF patient tissue — confirm explicitly in scoping if your program requires IPF-donor lungs.

IPF use cases:

• Compound screening on donor PCLS + fibrosis cocktail to induce IPF-like phenotype ex vivo
• Multi-arm comparisons with pro-fibrotic stimuli (TGF-β / bleomycin) and drug combinations

Caveats:

• Overlaps heavily with FibroFind — the real differentiator is donor supply network. Get written confirmation of IPF-donor availability, case numbers, preservation quality, and lead time before signing
• Japanese-language contracting is a clear advantage for Asia-based sponsors; non-Asia work goes through Glasgow

📎 Reference: ReproCELL — Precision-Cut Lung Slices

---

3-4. BioModels (Waltham, MA, USA) — Mid-tier full-service with MASH + IPF

Strengths: Boston-area mid-tier CRO with a public track record in IBD, pulmonary disease, and fibrosis models, including pulmonary fibrosis services. Public pages support IT bleomycin, modified Ashcroft, lung collagen, lung mechanics, and deep-learning-based IHC quantification (additional routes such as OP to confirm).

IPF use cases:

• Small-to-mid biotech Ph0/Ph1 that wants a standard assay battery delivered as a package
• Cross-project sponsors running MASH + IPF in parallel and seeking single-CRO logistics

Caveats:

• Ashcroft scoring is manual + imaging — no public disclosure of AI automation (April 2026)
• Aged-mouse work is case-by-case, not routine

📎 Reference: BioModels — Preclinical Contract Research Services

---

3-5. Charles River (Global) — Strong fit for a larger respiratory pharmacology package

Strengths: Largest-scale respiratory-services provider in the list. Public pages support mouse/rat bleomycin protocols with modified Ashcroft, hydroxyproline, image analysis of lung sections, BALF, and lung function. Has an in-house image analysis pipeline for Ashcroft reproducibility — one of the few vendors that documents a scoring-consistency process. Specific routes such as IT/OP and aerosol (nebulizer / micro-sprayer) are not all confirmable from that page alone, so confirm in the RFP (see tech_pulmonary_fibrosis_model_en for route selection).

IPF use cases:

• IND-enabling programs (GLP tox + efficacy) under one roof
• Need for aged mice (18-24 months), or alternative inducers (FITC, radiation) to triangulate mechanism
• Large sponsors that need global-scale capacity to run parallel studies across multiple sites

Caveats:

• Pricing is higher than mid-tier CROs — overkill for Ph0 exploration at a small biotech
• As a large organization, team quality varies. Verify the named PI's 3-year IPF publication record before signing

📎 Reference: Charles River — Pulmonary Fibrosis Models

---

4. Selection flowchart: which CRO fits your IPF project?

Use-case priority ranking

Scenario	First choice	Second choice
Ph0 mechanism exploration (human-first)	FibroFind or ReproCELL	—
Ph1 efficacy (standard bleomycin)	Charles River	Lovelace Biomedical
Human PCLS confirmation of in vivo hit	FibroFind	ReproCELL
IND-enabling (GLP tox + efficacy)	Charles River	—
Aged-mouse replication	Charles River	Lovelace Biomedical
Multi-inducer robustness	Lovelace Biomedical	Charles River
MASH + IPF parallel	BioModels	Charles River
Inhaled formulation × IPF model	Lovelace Biomedical	Charles River

---

5. Four checkpoints to verify "IPF specialty" from public info

✅ Check 1: Does the site list bleomycin delivery routes and dose ranges?

Vendors who explicitly list IT / OP / aerosol plus recommended dose ranges (e.g., 1.5-3.0 U/kg IT) usually have the capability to optimize per project. Sites that say only "bleomycin-induced pulmonary fibrosis" without detail are more likely to run a single fixed protocol — less useful when you need dose-escalation or route comparison.

✅ Check 2: Ashcroft scoring transparency

Ashcroft is notorious for inter-rater variability. Favor CROs that publish one of:

• Multi-rater blinded averaging (with ICC disclosed)
• Image analysis pipeline (digital scoring)
• AI / deep-learning automated scoring

If none of the above is publicly documented, deduct points — especially for go/no-go decision studies.

✅ Check 3: PCLS donor-tissue sourcing

Any CRO can say "we offer human PCLS." The real question is where the tissue comes from: a tissue bank, partnered hospital IRB, or in-house donor network. Lead time and case numbers vary dramatically. At quoting stage, ask, for example, whether they can deliver the IPF-donor PCLS sample numbers you need within your acceptable lead time.

✅ Check 4: Aged-mouse experience

IPF is a disease of the elderly. Efficacy in 8-12-week-old mice frequently fails to replicate at 18-24 months — aged fibrogenesis differs mechanistically (AT2 senescence, SASP, altered ECM turnover). CROs with publicly verifiable aged-mouse experience (e.g., studies run in 18-month C57BL/6J cohorts) are the only ones who can meaningfully test senescence-aware efficacy (see edu_ipf_vs_ppf_progression_en on AT2 senescence).

---

6. FAQ

Q1. Lovelace Biomedical vs Charles River for IPF — how do they compare? A. Depends on stage. For Ph0/Ph1 exploration where you want mechanism diversity (bleo + radiation + silica), Lovelace may be a better fit when multi-inducer respiratory pharmacology is central. Charles River is a strong candidate when a larger respiratory pharmacology package (e.g., GLP tox alongside efficacy) is needed. Both have documented bleomycin experience, but make the final call in the RFP after confirming delivery route, pathology scoring, recent track record, and capacity.

Q2. Can PCLS replace animal models? A. Useful for mechanism; not sufficient for efficacy decisions — consensus as of April 2026. PCLS captures cell-cell interactions, ECM production, and immune dynamics ex vivo, but cannot assess lung-function decline or long-term outcomes (FVC trajectory). Use human PCLS as an animal-to-human translational bridge, not a replacement for in vivo efficacy.

Q3. How much does aged-mouse work add to cost? A. There is no public pricing or official SLA. As a practical heuristic to confirm in the RFP, aged-mouse work tends to cost more than a standard project because of extended husbandry (raising mice to ~18 months) and larger N for variability correction — but the exact multiple varies widely by vendor and study design, so always confirm with an actual quote. Run aged mice as an add-on arm for final mechanism confirmation, not for the entire Ph1 program.

Q4. How does this differ from your MASH CRO comparison? A. MASH CRO Comparison 2026 focuses on liver fibrosis and in vitro 3D spheroids. This article focuses on lung fibrosis and in vivo bleomycin. Fibrosis CRO Landscape 2026 is the broad overview — this article has the deepest IPF-specific detail.

---

7. Related articles

• Pillar: IPF Drug Pipeline 2025-2026: Approvals, Failures & What's Next
• Sister CRO comparisons: Fibrosis CRO Landscape 2026 · MASH CRO Comparison 2026
• Model protocol: Bleomycin IPF Mouse Model: Dosing Protocol & Micro-Sprayer Guide
• Trend context: Specialty CRO Trends 2026
• Disease background: IPF vs PPF: Progression Patterns

---

📢 Editorial Disclosure

• We received no financial compensation, advertising fees, or affiliate commissions from any of the 5 CROs (Lovelace Biomedical / FibroFind / ReproCELL / BioModels / Charles River)
• Listing order is alphabetical within business-model groupings — neutral
• All evaluations draw solely from company websites, PubMed, ClinicalTrials.gov, and public press releases
• Information reflects public data as of June 2026 — always verify pricing and service scope directly with vendors

---

References

• Lovelace Biomedical — Pulmonary Fibrosis Preclinical Challenges
• FibroFind — Human tissue precision-cut slices
• ReproCELL — Precision-Cut Lung Slices
• BioModels — Preclinical Contract Research Services
• Charles River — Pulmonary Fibrosis Models
• Lehmann M, Krishnan R, Sucre J, et al. An Official American Thoracic Society Workshop Report: Precision-Cut Lung Slices — Emerging Tools for Preclinical and Translational Lung Research. Am J Respir Cell Mol Biol. 2025;72(1):16-31. PMID 39499861. PMC
• Tashiro J et al. Harnessing the translational power of bleomycin model. 2023. PubMed 38099140